Business Context and Reporting Period
Company: Bruker Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2010
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement) with Agilent Technologies, Inc.
Key Financial Metrics
Transaction Value: $37.5 million (cash purchase price).
Assets Acquired: Substantially all assets of certain Varian, Inc. businesses to be divested by Agilent.
Product Lines: Inductively coupled plasma mass spectroscopy (ICP-MS), laboratory gas chromatography (Lab GC), and gas chromatography triple-quadrupole mass spectrometry (GC-QQQ-MS) instruments.
Liabilities: Bruker will assume certain liabilities of Agilent relating to these businesses.
Other Financial Data: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Transaction Details
- Acquisition Scope: Bruker is acquiring development, manufacturing, marketing, distribution, sale, support, and maintenance rights for specific Varian product lines.
- Closing Conditions: Closing is subject to the consummation of the Agilent-Varian merger and receipt of government antitrust/competition approvals.
- Termination Date: If closing has not occurred by July 25, 2010 (extendable to August 24, 2010), either party may terminate the agreement without penalty.
- Employment: Bruker will offer employment to a majority of the employees of the acquired business.
Guidance, Outlook, and Related Agreements
Post-Closing Agreements:
- Intellectual Property Matters Agreement: Bruker will receive exclusive rights to certain IP and a license to other IP used in the business.
- Transition Services Agreement: Agilent will provide services to Bruker for a minimum of 180 days post-closing for agreed-upon fees.
- Symmetrical Supply Agreement: Agilent will supply components/products to Bruker; Bruker will supply Lab GC products and spare parts to Agilent.
Risks and Contingencies:
- Transaction is contingent on regulatory approvals.
- Standard indemnification provisions apply for breaches of representations, warranties, and covenants.
- IP licenses are subject to termination under specified circumstances.
Management Commentary: The full Asset Purchase Agreement will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2010.
Investor Verification Checklist
- Verify the status of the Agilent-Varian merger, as the Bruker acquisition is contingent upon its consummation.
- Monitor regulatory filings for antitrust and competition law approvals required for closing.
- Review the full Asset Purchase Agreement (expected in the Q1 2010 Form 10-Q) for detailed liability assumptions and IP license terms.
- Confirm the final closing date, noting the potential termination deadline of July 25, 2010 (or August 24, 2010).